menu
    • menu
    [{"orgOrder":0,"company":"Averitas Pharma","sponsor":"Averitas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Capsaicin","moa":"Vanilloid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Averitas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Averitas Pharma \/ Averitas Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Averitas Pharma \/ Averitas Pharma"},{"orgOrder":0,"company":"Averitas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Capsaicin","moa":"Vanilloid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Averitas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Averitas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Averitas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Averitas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Capsaicin","moa":"Vanilloid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Averitas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Averitas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Averitas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Averitas Pharma","sponsor":"Grunenthal","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Capsaicin","moa":"Vanilloid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Averitas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Averitas Pharma \/ Grunenthal","highestDevelopmentStatusID":"10","companyTruncated":"Averitas Pharma \/ Grunenthal"}]

    Find Clinical Drug Pipeline Developments & Deals by Averitas Pharma

    Menu

    Averitas Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Averitas Pharma

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Averitas Pharma

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Capsaicin

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Recipient : MD Anderson Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longit...

                            Details : Capsaicin is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Chemotherapy-induced Peripheral Nervous System Diseases.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            December 20, 2024

                            Lead Product(s) : Capsaicin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Recipient : MD Anderson Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Averitas Pharma

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Averitas Pharma

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Capsaicin

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Grunenthal

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Grünenthal Completes Recruitment for QUTENZA® Post-Surgical Neuropathic Pain Trial

                            Details : Qutenza (capsaicin) topical patch is approved for neuropathic pain associated with postherpetic neuralgia and diabetic peripheral neuropathy, being investigated for post-surgical neuropathic pain.

                            Product Name : Qutenza

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            November 07, 2024

                            Lead Product(s) : Capsaicin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Grunenthal

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Averitas Pharma

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Averitas Pharma

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Capsaicin

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First Patient Enrolled in a Phase III study with QUTENZA® in Post-Surgical Neuropathic Pain

                            Details : The Phase III study investigates the efficacy, safety, and tolerability of QUTENZA (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) to support an extension of the U.S. label.

                            Product Name : Qutenza

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            August 10, 2021

                            Lead Product(s) : Capsaicin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Averitas Pharma

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Averitas Pharma

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Capsaicin

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery

                            Details : Qutenza (Capsaicin) is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Neuralgia.

                            Product Name : Qutenza

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            July 19, 2021

                            Lead Product(s) : Capsaicin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth